Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Insider Sells $56,536.30 in Stock

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) insider Thomas Gad sold 10,810 shares of Y-mAbs Therapeutics stock in a transaction that occurred on Friday, March 7th. The shares were sold at an average price of $5.23, for a total transaction of $56,536.30. Following the completion of the sale, the insider now owns 202,721 shares of the company’s stock, valued at approximately $1,060,230.83. The trade was a 5.06 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.

Y-mAbs Therapeutics Stock Performance

NASDAQ YMAB opened at $4.91 on Thursday. The firm’s fifty day moving average price is $6.16 and its two-hundred day moving average price is $10.32. The stock has a market cap of $222.02 million, a PE ratio of -9.09 and a beta of 0.65. Y-mAbs Therapeutics, Inc. has a fifty-two week low of $4.25 and a fifty-two week high of $17.78.

Y-mAbs Therapeutics (NASDAQ:YMAB) last posted its earnings results on Tuesday, March 4th. The company reported ($0.15) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.02). The company had revenue of $26.50 million for the quarter, compared to the consensus estimate of $26.70 million. Y-mAbs Therapeutics had a negative return on equity of 24.61% and a negative net margin of 28.22%. During the same period in the previous year, the firm posted ($0.02) EPS. As a group, sell-side analysts predict that Y-mAbs Therapeutics, Inc. will post -0.65 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on YMAB. Morgan Stanley decreased their price objective on shares of Y-mAbs Therapeutics from $11.00 to $7.00 and set an “underweight” rating on the stock in a research note on Wednesday, March 5th. Bank of America decreased their price objective on shares of Y-mAbs Therapeutics from $14.00 to $12.00 and set a “neutral” rating on the stock in a research note on Wednesday, March 5th. Wedbush reissued an “outperform” rating and issued a $23.00 price objective on shares of Y-mAbs Therapeutics in a research note on Monday, March 3rd. Oppenheimer began coverage on shares of Y-mAbs Therapeutics in a research note on Monday, November 18th. They issued an “outperform” rating and a $23.00 price objective on the stock. Finally, HC Wainwright reissued a “buy” rating and issued a $22.00 price objective on shares of Y-mAbs Therapeutics in a research note on Monday, January 13th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, seven have issued a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $19.30.

Hedge Funds Weigh In On Y-mAbs Therapeutics

Hedge funds have recently modified their holdings of the business. Zurcher Kantonalbank Zurich Cantonalbank acquired a new position in shares of Y-mAbs Therapeutics during the third quarter worth $44,000. KLP Kapitalforvaltning AS acquired a new position in shares of Y-mAbs Therapeutics during the fourth quarter worth $46,000. Intech Investment Management LLC acquired a new position in shares of Y-mAbs Therapeutics during the third quarter worth $133,000. ProShare Advisors LLC acquired a new position in shares of Y-mAbs Therapeutics during the fourth quarter worth $99,000. Finally, Empire Financial Management Company LLC acquired a new position in shares of Y-mAbs Therapeutics during the third quarter worth $210,000. Institutional investors and hedge funds own 70.85% of the company’s stock.

About Y-mAbs Therapeutics

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.